Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research- United States

doi 10.1158/1078-0432.ccr-16-1415

Full Text

Abstract

Available in

Categories

Cancer Research

Date

September 8, 2016

Authors

V. A. Papadimitrakopoulou

Publisher

American Association for Cancer Research (AACR)

Related search

How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?

Journal of Thoracic Oncology

Respiratory Medicine

English

Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer

Cancer Research

Respiratory Medicine

English

Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

OncoTargets and Therapy

English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health

Occupational Health

English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology

English

Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial

The Lancet Oncology

English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology

Cancer Research

English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English